MA47408B1 - CANCER TREATMENT - Google Patents

CANCER TREATMENT

Info

Publication number
MA47408B1
MA47408B1 MA47408A MA47408A MA47408B1 MA 47408 B1 MA47408 B1 MA 47408B1 MA 47408 A MA47408 A MA 47408A MA 47408 A MA47408 A MA 47408A MA 47408 B1 MA47408 B1 MA 47408B1
Authority
MA
Morocco
Prior art keywords
cancer treatment
erdafitinib
relates
present
treating cancer
Prior art date
Application number
MA47408A
Other languages
French (fr)
Other versions
MA47408A (en
Inventor
Kim Stuyckens
Ruixo Juan Perez
Porre Peter De
Anjali Avadhani
Yohann Loriot
Arlene Siefker-Radtke
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47408A publication Critical patent/MA47408A/en
Publication of MA47408B1 publication Critical patent/MA47408B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La présente invention concerne un procédé de traitement du cancer par l'erdafitinibThe present invention relates to a method of treating cancer with erdafitinib

MA47408A 2017-12-20 2018-02-02 CANCER TREATMENT MA47408B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (2)

Publication Number Publication Date
MA47408A MA47408A (en) 2019-12-11
MA47408B1 true MA47408B1 (en) 2023-08-31

Family

ID=60702421

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47408A MA47408B1 (en) 2017-12-20 2018-02-02 CANCER TREATMENT

Country Status (5)

Country Link
EA (1) EA201991818A1 (en)
MA (1) MA47408B1 (en)
PT (1) PT3576740T (en)
TW (1) TWI798199B (en)
WO (1) WO2018141921A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220054483A1 (en) * 2018-09-21 2022-02-24 Janssen Pharmaceutica Nv Treatment of cholangiocarcinoma
CN113474337A (en) * 2018-12-19 2021-10-01 奥瑞生物药品公司 7- ((3, 5-dimethoxyphenyl) amino) quinoxaline derivatives as FGFR inhibitors for the treatment of cancer
JP2022521173A (en) * 2019-02-12 2022-04-06 ヤンセン ファーマシューティカ エヌ．ベー． Cancer treatment
CA3133348A1 (en) * 2019-03-15 2020-09-24 Poly-Med, Inc. In situ gel-forming delivery systems, methods and compositions
SG11202109854RA (en) * 2019-03-29 2021-10-28 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
SG11202112932QA (en) * 2019-05-31 2021-12-30 Qed Therapeutics Inc Methods of treating urinary system cancers
WO2021119108A1 (en) * 2019-12-09 2021-06-17 Cedars-Sinai Medical Center Use of fgfr inhibitors for treatment of idiopathic short stature
KR20220140781A (en) * 2020-02-12 2022-10-18 얀센 파마슈티카 엔.브이. FGFR tyrosine kinase inhibitors for the treatment of high-risk nonmuscular invasive bladder cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (en) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Also Published As

Publication number Publication date
EA201991818A1 (en) 2020-02-05
WO2018141921A1 (en) 2018-08-09
MA47408A (en) 2019-12-11
PT3576740T (en) 2023-08-18
TW201839399A (en) 2018-11-01
TWI798199B (en) 2023-04-11

Similar Documents

Publication Publication Date Title
MA47408B1 (en) CANCER TREATMENT
MA47501A (en) CYCLIC DI-NUCLEOTID DERIVATIVE FOR CANCER TREATMENT
BR112018077492A2 (en) Ovarian Cancer Treatment Methods
EA201791208A1 (en) Antibodies to CD38 for the treatment of acute myeloid leukemia
MA51418A (en) GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASES
EA201990296A1 (en) ANTIBODIES AGAINST SIGLEC-7 FOR CANCER TREATMENT
MA46459A (en) METHOD OF TREATMENT OF ACUTE KIDNEY DAMAGE
MX2020005567A (en) Methods of treatment with asparaginase.
EA202090510A1 (en) METHOD FOR TREATMENT OF LATERAL AMYOTROPHIC SCLEROSIS BY PRIDOPIDIN
EA201890185A1 (en) METHODS OF TREATMENT OF DISEASES MEDIATED BY GEPSID
NZ728636A (en) Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor
EA201792496A1 (en) METHODS OF TREATMENT OF INFLAMMATION OR NEUROPATHIC PAIN
MA46361A (en) TREATMENT OF PROSTATE CANCER
EA201791736A1 (en) COMBINED THERAPY FOR CANCER TREATMENT
MX2020012291A (en) Compounds for treatment of triple negative breast cancer and ovarian cancer.
EA201890442A1 (en) OBTAINING PHOTORECEPTORS FOR THE TREATMENT OF RETITAL DISEASES
MA53329A (en) EPILEPSY TREATMENT METHODS
SG10201900564WA (en) Methods for treating cancer
EA201792610A1 (en) METHOD OF TREATMENT OF NEUROLOGICAL DISEASE
MA51525A (en) MINERAL TREATMENT
MA55209A (en) METHODS OF TREATING AL AMYLODIS
MA54559A (en) POLYTHERAPY FOR THE TREATMENT OF CANCER
EA202090266A1 (en) MPO INHIBITORS FOR MEDICAL USE
MA56033A (en) METHODS OF TREATMENT FOR GENERALIZED SCLERODERMA
MA54465A (en) CXCR7 INHIBITORS FOR THE TREATMENT OF CANCER